USA flag logo/image

An Official Website of the United States Government

Development of a Novel Method for Inhibiting Atherosclerosis in Diabetes

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
80339
Program Year/Program:
2009 / STTR
Agency Tracking Number:
HL084857
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
VASCULAR PHARMACEUTICALS
1088 KNOLLRIDGE RD BURLINGTON, NC 27217-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2009
Title: Development of a Novel Method for Inhibiting Atherosclerosis in Diabetes
Agency: HHS
Contract: 2R42HL084857-02
Award Amount: $1,218,285.00
 

Abstract:

DESCRIPTION (provided by applicant): The long term objective of the proposed studies is to develop a monoclonal antibody that can be administered safely to patients with diabetes that will inhibit atherosclerosis. Insulin-like growth factor-I has been impl icated in the initiation of the proliferative phase of atherosclerotic lesion development but inhibiting IGF-I receptor activity may lead to toxicity. IGF-I functions cooperatively with the ?V?3 integrin to stimulate smooth muscle division and migration wh ich are related to the development of atherosclerosis. The purpose of these studies will be to determine if targeting the ?V?3 integrin disrupts IGF-I stimulated atherosclerotic lesion progression in pigs with diabetes. A secondary purpose will be to human ize the available mouse monoclonal antibody so that it can be administered safely to patients without inducing an immunogenic response. The current monoclonal antibody directed against the cysteine loop (amino acids 177-183 of the ? subunit of the ?V?3 int egrin) will be converted to a Fab2 fragment and purified. This Fab2 fragment will then be administered to pigs with diabetes for three months to determine if it inhibits the progressive enlargement of atherosclerotic lesions. Control pigs will receive an i rrelevant antibody. At the end of the treatment period, the carotid, femoral and coronary arteries will be analyzed to determine if antibody has inhibited the rate of atherosclerotic lesion progression. Additionally ultrasound of the femoral arteries will be used to determine if the antibody can induce lesion regression. Tissues will be removed and analyzed biochemically to determine that ?V?3 activation by the hyperglycemic stimulus has been inhibited and that IGF-I signaling is inhibited. Tissues will als o be tested to determine whether autoimmunization has occurred. In a second part of the study a humanized antibody will be prepared using the complementarity determining regions of the mouse antibody. These regions will grafted onto human framework sequenc es that are obtained from library of known human sequences. The sequence will then be scanned for regions of potential immunogenicity and peptides prepared and tested directly to determine if they have T-cell reactive epitopes. If immunogenic regions are p resent they will be modified by mutagenesis and tested to determine if immunogenicity has been removed. Further assessment of the 3 dimensional structure of the antibody will be undertaken to determine those residues that are within 10 angstroms of the CDR antigen binding site. These residues will also be modified to reduce their interaction with the binding domain. The final substituted humanized antibody will then be prepared using PCR and the full length gene product expressed. The purified product will then be tested for its ability to inhibit IGF-I stimulated smooth muscle cell proliferation and migration and clones will be analyzed to select those with the highest levels of expression that can be used in GMP manufacturing. The long term objective will be to prepare large scale quantities of the antibody for administration to human subjects. The treatment goal would be to administer to diabetic patients with atherosclerosis who have wide spread disease that is not amenable to current therapies. Since ath erosclerosis is the cause of death in 80% of diabetes and there is no currently available therapy that specifically treats this problem, there is a major need for new therapies that are directed toward treatment of this complication. PUBLIC HEALTH RELEVANC E: This project has very high relevance to public health. Atherosclerosis is the most common cause of death in patients with diabetes. It also leads to disability due to heart attacks, strokes and amputations. This project is seeking to develop a drug that will specifically inhibit the progression of atherosclerosis in patients with diabetes and that has the potential to prevent these complications.

Principal Investigator:

David R. Clemmons

Business Contact:

David Clemmons
Small Business Information at Submission:

VASCULAR PHARMACEUTICALS
1088 KNOLLRIDGE RD BURLINGTON, NC 27217

EIN/Tax ID: 120397286
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
Office of Sponsored Research
CHAPEL HILL, NC 27599-7406
RI Type: Nonprofit college or university